Skip to main content
Signal8

Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026

$REVBPress releaseMay 7, 2026, 4:16 PM ETRead the release

Revelation Biosciences reported Q1 2026 financial results, ending the period with $14.1 million in cash, which management believes is sufficient to fund operations into the first quarter of 2027. The company announced a key regulatory milestone, reaching an agreement with the FDA on a single adaptive Phase 2/3 study for the approval of Gemini in treating acute kidney injury.

Key figures

Guidance
fund operations through the first quarter of 2027
Net loss
3009051
Rd expense
1376861
Cash position
14113415
Warrant proceeds
6700000

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    REVB: Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026 — AI Analysis | Signal8